Aim: To identify the appropriate visceral adipose tissue (VAT) cutoff values for the diagnosis of abdominal obesity in predicting diabetes and the corresponding waist circumference in the Chinese population. Methods: At baseline, 381 volunteers aged 35-75 years were enrolled without diabetes from the Shanghai urban area. Anthropometry and VAT area determined by magnetic resonance imaging were measured. During the average 7.8 years of follow-up, glucose tolerance was monitored. Receiver operating characteristic (ROC) curve analysis was used to define the optimal cutoff points for abdominal obesity. Results: At the end of the study, 290 participants were followed up, in which 63 participants developed diabetes. Using ROC curve analyses in participants with normal glucose regulation, the appropriate VAT cutoff was 90 cm 2 for both genders to predict diabetes development. In logistic regression models, the relative risks (95% confidence intervals) of VAT value over 90 cm 2 were 3.35 (1.10-10.18, P ¼ 0.033) in men and 4.57 (1.73-12.07, P ¼ 0.002) in women after adjusted for age, impaired glucose regulation, hypertension and dyslipidemia. The optimal waist circumference cutoffs were 88 cm for men and 82 cm for women to indicate VAT value over 90 cm 2 in ROC analyses. Conclusion: VAT cutoff of 90 cm 2 is useful for defining visceral obesity in Chinese individuals. The appropriate waist circumference cutoffs for abdominal obesity are 88 cm for men and 82 cm for women in the Chinese population.

vivo study. Toll-like receptor (TLR)-stimulated human PBMCs or murine bone marrow-derived dendritic cells were used for in vitro study. Results Our study demonstrated that DZ2002 exerted a therapeutic effect on NZB/W F1 mice with established nephritis. The mechanism involves the modulation of T cell development in lupus by interfering with TLR-triggered APC function. Further study explored the regulatory mechanisms of SAHH on DC function in both innate and adaptive immune system, using the SAHH inhibitor with definite target and potent immunosuppressive activity. Conclusions The present issue demostrated that the reversible SAHH inhibitor DZ2002 effectively ameliorates lupus syndrome in NZB/W F1 mice by regulating TLR signaling-mediated APC responses. This compound is prospective to become a novel drug for SLE treatment with Hcy as a potential biomarker in autoimmune disease. Background and Aims Iguratimod (IGT) is a small molecular immunomodulatory drug and has been approved for treating rheumatoid arthritis. In our previous work, IGT ameliorates lupus-like disease in MRL/lpr mice by inhibiting abnormal B cell differentiation. The aim of this study is to further investigate the effects of IGT on human B cells. Methods We established a set of stimulations to induce naive human B cell into plasmablast (PB) in vivo. We also enrolled 7 patients with refractory lupus nephritis (LN) to assess the potential efficacy of IGT. Results IGT significantly attenuates the generation of CD19 +CD20-CD27hiCD38hi plasma cells upon both BCR-dependent and independent stimulations. IGT affects neither proliferation or apoptosis of B cell in vitro. In further investigation on B cell differentiation signalling pathwasys, we identifies that Blimp-1 and Xbp-1 can be remarkably impaired by IGT both in transcriptional and protein level; while Jak/STAT or NF-kB signalling are intact with IGT treatment. For explosive clinical study, seven patients with refractory LN were enrolled and administrated with IGT and steroids. ALL of these patients surprisingly show improved proteinuria after 8 week treatment. One patient quit the treatment because of anaemia. Conclusions IGT has a unique effect to arrest B cell terminal differentiation, which provides strong evidence that this drug could be a new candidate drug to treat B cell related autoimmune diseases such as lupus. 108 IGURATIMOD INHIBITS HUMAN B CELL TERMINAL DIFFERENTIATION IN VITRO AND MAY BENEFIT PATIENTS WITH REFRACTORY LUPUS NEPHRITIS